- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04711811
Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.
Individual Patient Expanded Access IND Using HB-adMSCs for the Treatment of Chronic Musculoskeletal Pain.
Study Overview
Detailed Description
Visit 1 - Screening During the screening visit, the principal investigator and/or delegated staff must provide a copy of the IRB-approved informed consent form * to the subject before performing any study procedure.
* IRB must provide a certificate action as proof of approval of the informed consent form.
The study subject should take enough time to read this essential document. If the study subject agrees to participate in the clinical trial, after reading the document, he/she must sign it. By giving his/her signature, study subject allows the principal investigator and/or designated staff to perform the following study procedures:
- Collection of Medical History.
- Collection of prior (up to a week before screening) and current medications.
- Evaluation of Inclusion and Exclusion Criteria.
- Measurement of Weight in lb. and Height in cm.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate.
- Physical Examination by the principal investigator.
- Video documentation of the subject walking and expressing the level of pain he/she presents at that visit.
Visits 2, 3, 4, 6 and 7. (Infusions 1, 2, 3, 5 and 6) Throughout these visits, the principal investigator and/or delegated staff will perform the following assessments:
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
Investigational Product Administration:
- Drug Name: HB-adMSCs
- Route: Intravenous
- Dose: 200 million
- Vital signs monitoring 2 hours post drug exposure. (Every 15 minutes for the first hour (0,15, 30, 45 and 60), and every 30 minutes for the second (90 and 120).
- 24 hours telephone encounter after Investigational Product Administration to assess incidence of adverse events or serious adverse events.
- Adverse Events monitoring.
Visit 5 (Infusions 4)
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
Investigational Product Administration:
- Drug Name: HB-adMSCs
- Route: Intravenous
- Dose: 200 million
- Vital signs monitoring 2 hours post drug exposure. (Every 15 minutes for the first hour (0,15, 30, 45 and 60), and every 30 minutes for the second (90 and 120).
- 24 hours telephone encounter after Investigational Product Administration to assess incidence of adverse events or serious adverse events.
- Adverse Events monitoring.
Visit 8 - Phone call Follow Up 1
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Adverse Events monitoring.
TREATMENT EXTENSION
After the study subject has completed Visit 7 - Infusion 6, the Principal Investigator will analyze the patient's data to determine if the next series of infusions should be provided. The criteria for making this conclusion are as follows:
- The patient must continue to meet inclusion/exclusion criteria for the study.
- The patient must be experiencing pain as evidenced by the VAS for pain.
- The patient must still be having difficulty in daily physical activities as evidenced by SF36 questionnaire.
- The patient must sign a new informed consent for treatment (s) extension.
Before leaving the infusion center, if the subject is authorized to receive the requested treatment extension, the subject must meet the following discharge criteria:
- Able to ambulate
- Respiration non-labored.
- Alert, oriented.
- SpO2 > 94 % on room air.
- SBP 100 to 139 mmHg & DBP 60 to 89 mmHg
- Heart Rate within normal limits (60 to 100 beats per minute)
Visits 9 and 15 (Infusion 7 and 12)
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
Investigational Product Administration:
- Drug Name: HB-adMSCs
- Route: Intravenous
- Dose: 200 million
- Vital signs monitoring 2 hours post drug exposure. (Every 15 minutes for the first hour (0,15, 30, 45 and 60), and every 30 minutes for the second (90 and 120).
- 24 hours telephone encounter after Investigational Product Administration to assess incidence of adverse events or serious adverse events.
- Adverse Events monitoring.
Visits 10, 11, 13, 14, 16 and 17 (Infusions 8, 9, 10, 11, 13 and 14)
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
Investigational Product Administration:
- Drug Name: HB-adMSCs
- Route: Intravenous
- Dose: 200 million
- Vital signs monitoring 2 hours post drug exposure. (Every 15 minutes for the first hour (0,15, 30, 45 and 60), and every 30 minutes for the second (90 and 120).
- 24 hours telephone encounter after Investigational Product Administration to assess incidence of adverse events or serious adverse events.
- Adverse Events monitoring.
Visit 12 - Follow Up Visit.
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
- Adverse Events monitoring.
Visit 18. (End of Study)
- Update Medical History Form if necessary.
- Update Concomitant medications list if applicable.
- Measurement of Weight in lb.
- Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.
- Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate.
- Completion of study questionaries by the subject.
- Physical Examination by the principal investigator.
- Adverse Events monitoring.
Study Type
Expanded Access Type
- Individual Patients
Contacts and Locations
Study Locations
-
-
Texas
-
Sugar Land, Texas, United States, 77478
- Hope Biosciences Stem Cell Research Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
IND # 27057
Inclusion Criteria:
- Subject is > 18 years of age at the time of signing the informed consent form.
- Subject has the diagnosis of chronic musculoskeletal pain for a least 1 year or VAS score > 7 a screening visit.
- Subject has provided informed consent before initiation of any study procedure.
- Subject and sexual partner if woman of childbearing potential must use a least 1 highly effective form of birth control* throughout the study and for 6 months after the last dose of the investigational product.
Exclusion Criteria:
- Subject has any active infection for which antibiotics were indicated within 4 weeks before screening.
- Subject has known alcoholic addiction or dependency, uses alcohol daily, or has current substance use or abuse.
- Subject has any active malignancy, including evidence of cutaneous basal, squamous cell carcinoma, or melanoma.
Subject has 1 or more significant concurrent medical conditions per investigator judgment, including the following:
- poorly controlled diabetes.
- chronic kidney disease
- heart failure
- myocardial infarction or unstable angina within 6 months prior to screening.
- uncontrolled hypertension
- Subject has received any stem cell treatment within 12 months before first dose of investigational product.
Subject has laboratory abnormalities during screening, including the following:
- White blood cell count < 3000/mm3
- Platelet count < 125,000mm3
- Absolute neutrophil count < 1500/mm3
- Subject has any other laboratory abnormality, which, in the opinion of the investigator poses a safety risk or will prevent the subject for completing the study.
- Subject is currently receiving treatment in another investigational drug study.
- Subject is unlikely to complete the study or adhere to the study procedures.
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBCMP01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, Chronic | Video-Assisted Thoracoscopic SurgeryTurkey
Clinical Trials on HB-adMSC
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableOsteo Arthritis Knee | Knee Pain ChronicUnited States
-
Hope Biosciences Stem Cell Research FoundationHope Biosciences; United Memorial Medical Center; River Oaks Hospital and ClinicsTerminatedCOVID-19United States
-
University Hospital, ToulouseRecruitingSystemic SclerosisFrance
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Johnson & Johnson Pte LtdShanghai China-Norm Management Consulting co.,LTD; Shanghai Skin Disease HospitalCompleted
-
Hookipa Biotech GmbHRecruitingHPV-Related Squamous Cell CarcinomaUnited States, Spain, Netherlands
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availablePost COVID-19 SyndromeUnited States
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonActive, not recruiting
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableParkinson DiseaseUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableAmyotrophic Lateral SclerosisUnited States